Boston-based RNA company Greenlight Biosciences is looking to bring its COVID-19 vaccine candidate into Phase III trials, and the partnership will speed up production for trials and – subject to regulatory approval – commercial scales .
The collaboration with Samsung will build on GreenLight’s existing manufacturing process, with the technology transfer from GreenLight to Samsung starting immediately.
Founded in 2008, GreenLight’s mission is to use RNA in human health and agriculture: including mRNA vaccines, therapeutics and a manufacturing platform.
Both companies emphasize their commitment to vaccine equity and the need to produce enough doses of mRNA vaccine for billions of people per year.
“We are delighted to partner with Samsung to manufacture messenger RNA for our Covid vaccine trial. There is an urgent need to develop vaccines for the whole world ”,said Andrey Zarur, CEO of GreenLight. “Our vaccine trial will pave the way for making vaccines accessible to everyone, not just citizens of developed countries. “
John Rim, CEO of Samsung Biologics, said: “We are delighted to partner with GreenLight to leverage our expertise in manufacturing a COVID-19 messenger RNA vaccine candidate to better serve patients in low-income countries.
“This collaboration is a major milestone for Samsung Biologics as we will begin our extended capabilities and operations to provide one-stop, end-to-end messenger RNA production, from drug substance (DS) to aseptic fill finish ( DP) through commercial release, all from one site.
“In this time of urgent global demand, we will strive to offer a seamless service across our entire biofabrication network to tackle the COVID pandemic and, in turn, help move towards the center’s goal. Korea vaccination. “
Samsung Biologics plans to add drug manufacturing capability for messenger RNA (DS) vaccines to the current Songdo facility, ready for cGMP operations early this year in 2022.